Street Calls of the Week
LONDON - Hemogenyx Pharmaceuticals plc (LSE:HEMO) will participate and present at the DCNY Summit in Washington, DC on September 18 and in New York on September 22, according to a press release statement.
The biotech company will showcase its clinical progress and pipeline, including updates on its ongoing Phase I clinical trial of CAR-T cell therapy for acute myeloid leukemia (AML).
The DCNY Summit brings together policymakers, investors, corporate leaders, and innovators. It is co-hosted by the Alliance Indus Foundation along with Congressional leaders, the Embassy of India, Saudi Vision Invest, and other international partners.
"We are honored to have been invited to present Hemogenyx at the DCNY Summit," said Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals.
The company plans to use the platform to highlight recent clinical milestones, showcase its therapeutic pipeline, and engage with potential investors and collaborators.
Previous participants in the summit have secured growth capital, according to the company statement. The event connects stakeholders from the fields of science, healthcare, and finance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.